| CHC patients with serum and plasma specimens (n = 97) | CHC patients treated with IFN and achieved RVR (n = 45) |
---|---|---|
Age (year) | 52.30 ± 8.20 | 52.64 ± 7.49 |
Gender (male/female) | 55/42 | 30/15 |
TBIL (μmol/L) | 16.90 ± 7.40 | / |
DBIL (μmol/L) | 7.47 ± 3.14 | / |
ALP (U/L) | 88.41 ± 31.01 | / |
GGT (U/L) | 79.79 ± 91.21 | / |
ALT (U/L) | 57.88 ± 50.87 | 119.71 ± 110.95 |
AST (U/L) | 45.50 ± 32.49 | 87.70 ± 82.70 |
PLT (×109/L) | 189.07 ± 66.50 | 166.60 ± 83.20 |
FibroScan | 9.44 ± 10.22 | 15.16 ± 7.63 |
MAL/DSA | Serum: 10.01 ± 1.94 | 9.29 ± 2.39 |
Plasma: 10.35 ± 2.30 | ||
AOL/DSA | Serum: 3.02 ± 3.43 | 6.34 ± 7.33 |
Plasma: 3.57 ± 4.78 |